Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction

Allergan0 sites75 target enrollmentNovember 2013

ConditionsMeibomian Glands

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Meibomian Glands
Sponsor: Allergan
Enrollment: 75
Primary Endpoint: Meibum Quality Score in the Study Eye as Assessed by the Investigator Using a 4-Point Scale
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This is an exploratory study to evaluate endpoints used to characterize participants with and without meibomian gland dysfunction (MGD) and will evaluate the correlation between signs and symptoms of MGD. No investigational drug will be administered in this study.

Registry

clinicaltrials.gov

Start Date

November 2013

End Date

July 2014

Last Updated

11 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Allergan

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Participants characterized as with or without Meibomian Gland Dysfunction.

Exclusion Criteria

•Lid heating therapy, therapeutic gland expression, or meibomian gland probing within 12 months of enrollment
•Contact lens use in the 30 days prior to enrollment
•Lid hygiene within 48 hours prior to enrollment
•Use of eye makeup within 8 hours of enrollment
•Eyelash growth-stimulating products within 30 days prior to enrollment
•Use of systemic vitamins and/or systemic supplements containing omega 3 fatty acids within 60 days of enrollment
•Use of systemic anti-histamines within 30 days prior to enrollment.